Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same author

Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.

Blood cancer journal·2026
Same author

Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.

Case reports in hematology·2026
Same author

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

Bone marrow transplantation·2026
Same author

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Blood cancer journal·2026
Same author

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Blood·2026
Same journal

Public Health Response to Clade Ib Mpox with Multiple Exposures in Congregate Living Settings - New Hampshire, February 2025.

NEJM evidence·2026
Same journal

Berberine-Ursodeoxycholate - Bringing Traditional Chinese Medicine to Our World.

NEJM evidence·2026
Same journal

Outbreak of Legionnaires' Disease Associated with Cooling Tower Systems in Central Harlem.

NEJM evidence·2026
Same journal

Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency.

NEJM evidence·2026
Same journal

A Randomized Trial of Interval Likelihood Ratios for Clinical Decision-Making.

NEJM evidence·2026
Same journal

Evidence for Evidence-Based Medicine - A Call for Some Theory and a New Problem.

NEJM evidence·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Intermediate-Dose Cytarabine as Postinduction AML Therapy.

Mathilde Hunault1, Cécile Pautas2, Sarah Bertoli3

  • 1Department of Hematology, Centre Hospitalier Universitaire (CHU) d'Angers, Centre de Recherche en Cancérologie et Immunologie Intégré de Nantes/Angers (CRCI2NA), Institut National de la Santé et de la Recherche Médical (INSERM) - Unit U1307, Centre National de la Recherche Scientifique (CNRS) - Unit UMR6075, Fédération Hospitalo-Universitaire Grand Ouest Against Leukemia (GOAL), Université d'Angers, Angers, France.

NEJM Evidence
|June 24, 2025
PubMed
Summary
This summary is machine-generated.

Intermediate-dose cytarabine (IDAC) shows noninferior overall survival compared to high-dose cytarabine (HDAC) in newly diagnosed acute myeloid leukemia (AML) patients. This study found similar or lower toxicities with IDAC, making it a viable postinduction therapy option.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

284

Related Experiment Videos

Last Updated: Jun 16, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

284

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Acute myeloid leukemia (AML) is a significant hematologic malignancy.
  • Postinduction chemotherapy plays a crucial role in AML treatment.
  • Comparing different cytarabine dosing strategies is essential for optimizing patient outcomes.

Purpose of the Study:

  • To evaluate the noninferiority of intermediate-dose cytarabine (IDAC) versus high-dose cytarabine (HDAC) in overall survival (OS).
  • To assess the safety and toxicity profiles of IDAC compared to HDAC as postinduction therapy for AML.
  • To determine the efficacy of IDAC in a specific adult patient cohort.

Main Methods:

  • A randomized controlled trial was conducted involving patients aged 18-60 with newly diagnosed AML.
  • Patients received either IDAC (1500 mg/m²/12 hours) or HDAC (3000 mg/m²/12 hours) postinduction.
  • Overall survival (OS) was the primary endpoint, with analyses adjusted for European Leukemia Net (ELN) 2022 risk group, anthracycline use, induction response, and allogeneic stem cell transplantation (HSCT).

Main Results:

  • At 5 years, OS was 59.3% for IDAC versus 57.5% for HDAC, demonstrating noninferiority (adjusted hazard ratio, 0.96; P=0.0042).
  • No significant interaction was found between treatment effect and patient subgroups (e.g., ELN 2022 risk group).
  • IDAC was associated with lower severity of myelosuppression and fewer related adverse events compared to HDAC.

Conclusions:

  • Intermediate-dose cytarabine (IDAC) offers noninferior overall survival outcomes compared to high-dose cytarabine (HDAC) in newly diagnosed AML patients.
  • IDAC demonstrates a favorable safety profile with similar or reduced toxicities.
  • These findings support IDAC as an effective and potentially safer postinduction therapy option for AML.